Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$3.63
+4.2%
$2.47
$1.43
$3.99
$362.98M1.56169,172 shs402,077 shs
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$14.50
-9.9%
$12.56
$5.01
$18.70
$100.85M0.25101,847 shs83,337 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$4.21
-7.4%
$4.02
$1.61
$9.50
$351.40M11.49 million shs1.80 million shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$13.86
-1.5%
$10.67
$3.90
$14.93
$1.34B1.681.15 million shs1.46 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
-1.14%+11.18%+58.18%+70.59%+2.65%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+1.45%+11.05%+34.67%+74.21%+105.89%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-5.60%+6.31%+17.57%+34.62%-35.37%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-1.40%+24.38%+29.06%+26.85%+51.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$3.63
+4.2%
$2.47
$1.43
$3.99
$362.98M1.56169,172 shs402,077 shs
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$14.50
-9.9%
$12.56
$5.01
$18.70
$100.85M0.25101,847 shs83,337 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$4.21
-7.4%
$4.02
$1.61
$9.50
$351.40M11.49 million shs1.80 million shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$13.86
-1.5%
$10.67
$3.90
$14.93
$1.34B1.681.15 million shs1.46 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
-1.14%+11.18%+58.18%+70.59%+2.65%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+1.45%+11.05%+34.67%+74.21%+105.89%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-5.60%+6.31%+17.57%+34.62%-35.37%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-1.40%+24.38%+29.06%+26.85%+51.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune stock logo
ACIU
AC Immune
2.25
Hold$10.00175.86% Upside
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.50
Moderate Buy$21.0044.88% Upside
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
2.80
Moderate Buy$16.71296.83% Upside
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
2.70
Moderate Buy$17.2924.70% Upside

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, LRMR, and ACIU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
AC Immune stock logo
ACIU
AC Immune
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/8/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/2/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$26.00 ➝ $21.00
9/30/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$10.00 ➝ $7.00
9/30/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$15.00 ➝ $11.00
9/27/2025
AC Immune stock logo
ACIU
AC Immune
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
9/27/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune stock logo
ACIU
AC Immune
$28.92M12.59N/AN/A$1.29 per share2.81
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$128.94M0.79N/AN/A($16.89) per share-0.86
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$2.69 per shareN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/A$3.45 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune stock logo
ACIU
AC Immune
-$57.83M-$0.58N/AN/AN/A-174.94%-49.35%-23.16%11/4/2025 (Estimated)
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$0.43N/AN/AN/A3.07%-8.34%6.61%11/11/2025 (Estimated)
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$80.60M-$1.56N/AN/AN/AN/A-62.92%-53.98%10/29/2025 (Estimated)
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)

Latest ATRA, ORIC, LRMR, and ACIU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
AC Immune stock logo
ACIU
AC Immune
-$0.23N/AN/AN/A$0.81 millionN/A
10/29/2025Q3 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.40N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.47-$0.41+$0.06-$0.41N/AN/A
8/12/2025Q2 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.46-$0.47-$0.01-$0.47N/AN/A
8/11/2025Q2 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$0.32$0.19+$0.51$0.19$4.23 million$17.58 million
8/5/2025Q2 2025
AC Immune stock logo
ACIU
AC Immune
-$0.20-$0.25-$0.05-$0.25$1.98 million$1.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune stock logo
ACIU
AC Immune
N/A
1.33
1.33
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
1.70
1.70
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
5.46
5.46
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/A
16.13
16.13

Institutional Ownership

CompanyInstitutional Ownership
AC Immune stock logo
ACIU
AC Immune
51.36%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
95.05%

Insider Ownership

CompanyInsider Ownership
AC Immune stock logo
ACIU
AC Immune
4.60%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.00%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4.50%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
6.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune stock logo
ACIU
AC Immune
140100.41 million95.79 millionOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3307.02 million6.74 millionOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3082.78 million79.05 millionOptionable
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
8097.12 million90.50 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AC Immune stock logo

AC Immune NASDAQ:ACIU

$3.62 +0.15 (+4.17%)
As of 03:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$14.50 -1.59 (-9.86%)
As of 03:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$4.21 -0.34 (-7.43%)
As of 03:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Oric Pharmaceuticals stock logo

Oric Pharmaceuticals NASDAQ:ORIC

$13.86 -0.22 (-1.55%)
As of 03:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.